| Strengths | Limitations |
---|---|---|
National Poison Data System (NPDS) | • Structured data collection forms with required fields and common product database • National coverage • Medical management cases including follow-up and disposition when possible, often with healthcare providers • Timely availability of data • Legacy data since 1983 | • Not all exposures are reported • Self-reported exposures; most from non-clinical reporters |
FDA Adverse Event Reporting System (FAERS) | • Structured data collection forms • Publicly accessible datasets • Regulated reporting requirements • Legacy data since 1998 | • Spontaneous reports; not all cases are reported • Changes in reporting requirements over time • Inconsistencies in reporting practices by manufacturers • Self-reported cases; many from non-clinical reporters • Duplicate cases • Incomplete reports • Delays in public data access |
English Language Medical Literature | • Peer-reviewed publication • Detailed clinical course | • Unstructured data • Not all cases are reported • Reporter bias (author and journal editors determine what may be of interest to report) |
Participating Manufacturer Postmarket Safety Databases | • Structured data collection forms • Follow-up and disposition documented when possible, often with healthcare providers | • Spontaneous reports; not all cases are reported • Self-reported cases; many from non-clinical reporters • Inconsistencies in documentation practices by manufacturers |
News/media Reports | • Often include contextual information about exposures • Higher likelihood of detecting fatal events • Timely reporting | • Unstructured data • Not all cases are reported • Reporter bias (journalist determines what is of interest to report) • Non-clinical reporters |